LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Search

Insulet Corp

Open

Sector Healthcare

236.33 0.38

Overview

Share price change

24h

Current

Min

235.2

Max

240.52

Key metrics

By Trading Economics

Income

137M

189M

Sales

47M

489M

P/E

Sector Avg

60.6

104.138

EPS

0.55

Profit margin

38.608

Employees

3,000

EBITDA

-3.1M

81M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+5.81 upside

Dividends

By Dow Jones

Next Earnings

7 Nov 2024

Market Stats

By TradingEconomics

Market Cap

448M

16B

Previous open

235.95

Previous close

236.33

News Sentiment

By Acuity

9%

91%

8 / 390 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Insulet Corp Chart

Past performance is not a reliable indicator of future results.

Related News

30 Nov 2023, 17:43 UTC

Earnings

Salesforce, Insulet, and Datadog Are November's Top Performers -- and These Are the Worst -- Barrons.com

17 Nov 2023, 12:00 UTC

Top News

Obesity Drugs Put These Stocks on a Crash Diet, and Now They're Rebounding -- Heard on the Street -- WSJ

Peer Comparison

Price change

Insulet Corp Forecast

Price Target

By TipRanks

5.81% upside

12 Months Forecast

Average 249.29 USD  5.81%

High 285 USD

Low 185 USD

Based on 17 Wall Street analysts offering 12 month price targets forInsulet Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

14

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

233.1901 / 236.59Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

8 / 390 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Insulet Corp

Insulet Corporation is primarily engaged in the development, manufacture and sale of its proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.